Atossa (ATOS) CEO Steven Quay granted 950,000 options and RSUs

Rhea-AI Filing Summary

Atossa Therapeutics President & CEO Steven C. Quay, who also serves as a director, reported new equity awards dated January 20, 2026. He received 325,203 restricted stock units (RSUs), each representing one share of common stock, which will vest one year from the grant date. He was also granted 950,000 stock options with an exercise price of $0.603, vesting quarterly over 24 months following January 20, 2026, contingent on continued service.

Following these awards, Quay directly beneficially owns 339,101 shares of common stock and indirectly holds 22,254 shares through Ensisheim Partners, LLC, an entity he co‑owns with Dr. Shu‑Chih Chen, with shared voting and investment power and a disclaimer of beneficial ownership beyond his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

QUAY STEVEN C

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.,

1448 NW MARKET STREET, SUITE 500

(Street)

SEATTLE WA 98107

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/20/2026		A		325,203	A	$0.0	339,101	D
Common Stock								22,254	I	By Ensisheim Partners, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.603	01/20/2026		A		950,000		(3)	01/20/2026	Common Stock	950,000	$0.603	950,000	D

Explanation of Responses:

1. Represents the acquisition of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction date.

2. Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

3. The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026.

	/s/ Steven C. Quay	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ATOS President & CEO Steven C. Quay report?

Steven C. Quay reported equity awards dated January 20, 2026, including 325,203 restricted stock units (RSUs) and 950,000 stock options linked to Atossa Therapeutics common stock.

How many Atossa Therapeutics RSUs were granted to Steven C. Quay and when do they vest?

Steven C. Quay was granted 325,203 RSUs, each representing one share of Atossa Therapeutics common stock. These RSUs vest one year from the January 20, 2026 grant date.

What are the key terms of the 950,000 Atossa stock options granted to Steven C. Quay?

Quay received 950,000 stock options with an exercise price of $0.603 per share, matching the closing stock price on January 20, 2026. The options vest on a quarterly basis over 24 months following that date, subject to his continued service.

How many Atossa Therapeutics shares does Steven C. Quay beneficially own after these transactions?

After the reported awards, Quay directly beneficially owns 339,101 shares of Atossa Therapeutics common stock and indirectly holds 22,254 shares through Ensisheim Partners, LLC.

What is Ensisheim Partners, LLC in relation to Steven C. Quay’s ATOS holdings?

Ensisheim Partners, LLC is wholly owned by Steven C. Quay and Dr. Shu‑Chih Chen. They share voting and investment power over 22,254 Atossa shares held by Ensisheim, and Quay disclaims beneficial ownership beyond his pecuniary interest.

Did Steven C. Quay pay cash for the 325,203 Atossa RSUs reported?

The filing lists the 325,203 RSUs at a price of $0.0 per share, indicating these were grants of restricted stock units rather than open‑market purchases.